

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### **Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

During scoping the company raised that the prevalence of NPC can be higher in some ethnic minority groups such as Southern Chinese, Northern African, and Alaskan origin.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

An impact of the appraisal will be considered by committee.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No additional stakeholders have been identified during the scoping process.

**Approved by Associate Director (name): Ross Dent**

**Date:** 16/12/2025